Trial Profile
Mesylate Apatinib for Stage Ⅳ Soft Tissue Sarcoma Patients After Failure of Traditional Chemotherapy: Prospective, Open-label, Single-Arm, Multi-center Phase II Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 04 Jun 2019 Results assessing chemotherapy combined with antiangiogenesis drugs in stage IV sarcoma patients using data from NCT03121833 and NCT03121846 studies, presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Results (n=42) assessing efficacy and safety of Apatinib for patients with stage IV soft tissue sarcoma published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 19 May 2017 Status changed from not yet recruiting to recruiting.